Chimeric antigen receptor T-cell neuropsychiatric toxicity in acute lymphoblastic leukemia

Palliative and Supportive Care

Volumn 15, Issue 4, 2017, Pages 499-503

  Prudent, Vasthie ^a,b   Breitbart, William S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Acute lymphoblastic leukemia; Chimeric antigen receptor; Cytokine release syndrome; Neurotoxicity

Indexed keywords

CHIMERIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; COMPLICATION; FEMALE; HUMAN; MALE; METABOLISM; TOXICITY AND INTOXICATION;

ADULT; CHIMERIN PROTEINS; FEMALE; HUMANS; MALE; NEUROTOXICITY SYNDROMES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, ANTIGEN, T-CELL;

EID: 85008331152     PISSN: 14789515     EISSN: 14789523     Source Type: Journal    
DOI: 10.1017/S147895151600095X     Document Type: Article

References (16)

1. Barrett, D.M., Teachey, D.T. &Grupp, S.A. (2014). Toxicity management for patients receiving novel T-cell engaging therapies. Current Opinion in Pediatrics, 26(1), 43-49 Available from https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC4198063/pdf/nihms607686.pdf
2. Cao, Y., Rodgers, D.T., Du, J., et al. (2016). Design of switchable chimeric antigen receptor T cells targeting breast cancer. Angewandte Chemie (International Ed. in English), 55(26), 7520-7524. Epub ahead of print May 4
3. Deng, Z.,Wu, Y., Ma,W., et al. (2015). Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM. BMC Immunology, 16, 1 Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318 439/pdf/12865-2014-Article-64.pdf
4. Davila,M.L., Riviere, I.,Wang, X., et al. (2014). Efficacy and toxicity management of 19-28z CAR-Tcell therapy in B cell acute lymphoblastic leukemia. Science Translational Medicine, 6(224), 224ra25 Available from https://www. ncbi.nlm.nih.gov/pmc/articles/PMC4684949/pdf/nihms 744123.pdf
5. Drent, E., Groen, R.W., Noort, W.A., et al. (2016). Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Haematologica, 101(5), 616-625. Epub ahead of print Feb 8 Available from https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC5004365/pdf/1010616.pdf
6. Fisher, D.T., Chen, Q., Skitzki, J.J., et al. (2011). IL-6 transsignaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. Journal of Clinical Investigation, 121(10), 3846-3859. Epub ahead of print Sep 19 Available from https://www. ncbi.nlm.nih.gov/pmc/articles/PMC3195455/pdf/JCI 44952.pdf
7. Giordano Attianese, G.M., Marin, V., Hoyos, V., et al. (2011). In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor. Blood, 117(18), 4736-4645. Epub ahead of print Mar 15 Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC 3100686
8. Gruol, D.L. (2015). IL-6 regulation of synaptic function in the CNS. Neuropharmacology, 96(Pt. A), 42-54. Epub ahead of print Nov 22, 2014 Available from https:// www.ncbi.nlm.nih.gov/pmc/articles/PMC4446251/pdf/ nihms644784.pdf
9. Lee, D.W., Gardner, R., Porter, D.L., et al. (2014). Current concepts in the diagnosis and management of cytokine release syndrome. Blood, 124(2), 188-195. Epub ahead of print May 29 Available from https://www.ncbi.nlm. nih.gov/pmc/articles/PMC4093680
10. Lee, D.W., Kochenderfer, J.N., Stetler-Stevenson, M., et al. (2015). T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet, 385(9967), 517-528. Epub ahead of print Oct 13, 2014
11. Maude, S.L., Frey, N., Shaw, P.A., et al. (2014a). Chimeric antigen receptor T cells for sustained remissions in leukemia. The New England Journal of Medicine, 371(16), 1507-1517 Available from http://www.nejm.org/doi/ pdf/10.1056/NEJMoa1407222
12. Maude, S.L., Barrett, D., Teachey, D.T., et al. (2014b). Managing cytokine release syndrome associated with novel T-cell-engaging therapies. Cancer Journal, 20(2), 119-122 Available from https://www.ncbi.nlm.nih. gov/pmc/articles/PMC4119809/pdf/nihms607703.pdf
13. Maus, M.V., Grupp, S.A., Porter, D.L., et al. (2014). Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood, 123(17), 2625-2635. Epub ahead of print Feb 27 Available from https:// www.ncbi.nlm.nih.gov/pmc/articles/PMC3999751
14. Porter, D.L., Hwang,W.T., Frey, N.V., et al. (2015). Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science TranslationalMedicine, 7(303), 303ra139
15. Ritchie, D.S., Neeson, P.J., Khot, A., et al. (2013). Persistence and efficacy of second generation CAR T cell against the LeYantigen in acute myeloid leukemia. Molecular Therapy, 21(11), 2122-2129. Epub ahead of print Jul 8 Available from https://www.ncbi.nlm.nih. gov/pmc/articles/PMC3831035/pdf/mt2013154a.pdf
16. Tasian, S.K. &Gardner, R.A. (2015). CD19-redirected chimeric antigen receptor-modified Tcells: A promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL). Therapeutic Advances in Hematology, 6(5), 228-241 Available from https:// www.ncbi.nlm.nih.gov/pmc/articles/PMC4556967/pdf/ 10.1177-2040620715588916.pdf